Athenex Inc (ATNX)

NASDAQ
0.584
-0.526(-47.38%)
  • Volume:
    13,676,430
  • Day's Range:
    0.584 - 0.619
  • 52 wk Range:
    0.405 - 3.910
Unusual trading volume

ATNX Overview

Prev. Close
1.11
Day's Range
0.584-0.619
Revenue
120.99M
Open
0.6
52 wk Range
0.405-3.91
EPS
-1.72
Volume
13,676,430
Market Cap
71.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,388,355
P/E Ratio
-0.549
Beta
1.08
1-Year Change
-68.38%
Shares Outstanding
121,608,388
Next Earnings Date
Nov 10, 2022
What is your sentiment on Athenex?
or
Vote to see community's results!

Athenex Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Athenex Inc Analysis

Athenex Inc Company Profile

Athenex Inc Company Profile

Employees
659

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellSellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Awful numbers....-20% today for sure
    2
    • Tomorow big day up?
      0
      • So.......8 days from today. What do you think?
        0
        • BUFFALO, N.Y., March 07, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Tuesday, March 15, 2022. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.
          0
          • Earnings announcement* for ATNX: Mar 07, 2022Athenex, Inc. is estimated to report earnings on 03/07/2022. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.04. The reported EPS for the same quarter last year was $-0.53.
            0
            • What time the numbers will be relais
              0
              • Numbers are not good
                0
                • P/B could be 1, so at about 1.9$ it will flatten?
                  0
                  • It's done. Path to 0
                    1
                    • Does it have any catalyst left to look fowrward to?
                      0